{"prompt": "['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 10 of 169', '10.3.1.2 Eczema Area and Severity Index', '68', '10.3.1.3', 'Scoring Atopic Dermatitis', '70', '10.3.2', 'Subject assessments', '71', '10.3.2.1 Eczema-related Sleep numeric rating scale', '71', '10.3.2.2 Worst Daily Pruritus numeric rating scale', '71', '10.3.2.3 Average Daily Pruritus numeric rating scale', '71', '10.3.2.4', 'Patient Global Impression of Bother', '71', '10.3.2.5', 'Patient Global Impression of Severity', '71', '10.3.2.6', 'Patient-Oriented Eczema Measure', '72', '10.3.2.7', 'Dermatology Life Quality Index', '72', '10.3.2.8', 'EQ-5D-5L', '72', '10.3.2.9', 'SF-36', '73', '10.3.2.10 Work Productivity and Activity Impairment - General Health', '73', '10.3.2.11 Hospital Anxiety and Depression Scale', '74', '10.3.2.12 Treatment Satisfaction Questionnaire for Medicine', '74', '10.4 Safety assessments', '74', '10.4.1 Vital signs', '74', '10.4.2 Physical examination', '75', '10.4.3', 'Digital ECG', '75', '10.4.4', 'Pregnancy test', '76', '10.4.5 Laboratory testing', '76', '10.4.6 Pharmacokinetic assessments', '78', '10.4.7 Anti-drug antibodies measurements', '78', '10.5 Other assessments and photography', '79', '10.5.1 Skin microbiology', '79', '10.5.1.1 Background and rationale', '79', '10.5.1.2', 'Staphylococcus aureus colonisation (all subjects)', '79', '10.5.1.3', 'Skin microbiome characterisation (selected trial sites)', '80', '10.5.2', 'Serum biomarkers', '80', '10.5.2.1', 'Rationale', '80', '10.5.2.2 Small biomarker panel (all subjects)', '81', '10.5.2.3', 'Large biomarker panel (selected trial sites)', '81', '10.5.3', 'Skin biopsies (selected trial sites)', '81', '10.5.4', 'Storage of biological samples', '82', '10.5.5 Photography (selected trial sites)', '83', '10.6 Estimate of total blood volume collected', '83', '11 Adverse events', '84', 'eDoc-00631888 - Version 4.0']['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 11 of 169', '11.1 Collection of adverse events', '84', '11.2 Reporting of adverse events', '84', '11.3 Reporting of serious adverse events', '85', '11.3.1 Investigator reporting responsibilities', '85', '11.3.2 LEO reporting responsibilities', '86', '11.4 Other events that require expedited reporting', '86', '11.4.1 Pregnancy', '86', '11.5 Reporting of other events', '87', '11.5.1 Adverse events of special interest', '87', '11.5.2 Overdose', '88', '11.5.3', 'Medication error', '88', '11.5.4', 'Misuse', '88', '11.5.5', 'Abuse', '89', '11.5.6 Aggravation of condition', '89', '11.6 Follow-up for final outcome of adverse events', '89', '11.7 Handling of an urgent safety measure', '89', '12 Statistical methods', '91', '12.1 Sample size', '91', '12.2 Trial analysis sets', '91', '12.3 Statistical analysis', '93', '12.3.1 Disposition of subjects', '93', '12.3.2 Demographics and other baseline characteristics', '93', '12.3.3 Exposure and treatment compliance', '93', '12.3.3.1 Exposure', '93', '12.3.3.2 Treatment compliance', '94', '12.3.4 Multiple testing procedure', '94', '12.3.5 Analysis of initial treatment', '95', '12.3.5.1 Analysis of primary endpoints', '95', '12.3.5.1.1 Primary estimand: \"composite\\'', '96', '12.3.5.1.2 Secondary estimand: \"hypothetical\\'', '97', '12.3.5.1.3 Tertiary estimand: \"treatment policy\\'', '100', '12.3.5.2', 'Analysis of secondary endpoints', '101', \"12.3.5.2.1 Primary estimand for the continuous secondary endpoints: *hypothetical'\", '101', '12.3.5.2.2 Secondary estimand for the continuous secondary endpoints: \"treatment policy\\'', '103', '12.3.5.3 Analysis of additional secondary endpoints', '105', 'eDoc-00631888 - Version 4.0']\n\n###\n\n", "completion": "END"}